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Folic Acid (FA)-tagged protein nanoemulsions were found to be preferentially internalized on B-cell lymphoma cell line (A20 cell line),
which, for the first time, is reported to express folate receptor (FR)-alpha. Carbon monoxide releasing molecule-2 (CORM-2) was
incorporated in the oil phase of the initial formulation. FA-functionalized nanoemulsions loaded with CORM-2 exhibited a considerable
antitumor effect and an increased survival of BALB/c mice bearing subcutaneous A20 lymphoma tumors. The developed nanoemulsions also
demonstrated to be well tolerated by these immunocompetent mice. Thus, the results obtained in this study demonstrate that FA-tagged
protein nanoemulsions can be successfully used in cancer therapy, with the important ability to delivery drugs intracellularly.
© 2015 Elsevier Inc. All rights reserved.
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Nanocarriers can modulate the pharmacokinetic and drug tissue
distribution profile.1,2 Specific anticancer drug delivery is promoted
including targeting ligands,1,3–5 such as folic acid (FA).6 FA and
FA conjugates bind with high affinity to folate receptor (FR)-alpha
and -beta, and enter FR-expressing cells by receptor-mediated
endocytosis.7 FR-alpha expression is restricted to various normal
epithelial cells, however it is overexpressed in several malignant
cells and tissues.8 FR-beta is a differentiation marker in normal
hematopoiesis, being restricted to the myelomonocytic lineage and
increasing during neutrophil maturation. FR-beta expression is also
increased in activated monocytes/macrophages.8 FA has emerged
as an optimal targeting ligand with simple conjugation chemistry,
non-immunogenicity and high affinity for the FR (Kd = 10
−10 M)
even after conjugation.9 Nanocarriers functionalized with FA are
widely studied for cancer targeting aplications.
Carbon monoxide (CO) has shown beneficial effects in
mammals.10–13 CO can induce growth arrest of human cancer
cells, as well as murine AC29 mesothelioma cells.14 The first
compound described as able to carry and deliver controlled
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uthenium(II) dimer ([Ru(CO)3Cl2]2), known as CORM-2 (Carbon
monoxide releasing molecule-2).10,11,15–17 Ru has also been used
independently in a variety of experimental anti-cancer drugs, with
no acute or sub-acute toxicities reported.15,18
CORMs have been described as exhibiting a wide range of
biological effects resulting in specific responses, which involve a
restricted number of intracellular pathways and targets that
encompass inflammation, apoptosis and cellular proliferation.16
CORM-2, in particular, has been described to promote a
beneficial therapeutic outcome in a number of mouse models
of human disease.15 However, CORM-2 has been shown to be
highly unstable in plasma. Together with its observed anti-
proliferative capacity,19,20 this supports the advantage of
targeted delivery of CORM-2 to cancer cells.
Here, we report the development of FA-tagged protein
nanoemulsions loaded with CORM-2 for targeted drug delivery
in a B-cell lymphoma model. Nanoemulsions were produced by
high pressure homogenization of an aqueous phase (BSA
solution containing a PEGylated surfactant and BSA–FA
conjugate) with an organic phase (vegetable oil). Small, stable,
PEGylated (described elsewhere21) and FA-functionalized
nanoemulsions were obtained and evaluated in terms of specific
uptake using a lymphoma cell line (A20 cell line). The biological
effect of the nanoemulsions loaded with CORM-2 was tested
both in vitro and in vivo. The results obtained suggest the use of
FA-tagged protein nanoemulsions for targeted drug delivery in
cancer therapy.Methods
Nanoemulsion preparation
Nanoemulsions were prepared using a high pressure
homogenizer (APV-2000, Denmark). BSA (Sigma-Aldrich,
USA) and PEGylated surfactant (Sigma-Aldrich, USA) were
dissolved in phosphate buffer saline (PBS), pH 7.4, at
concentration of 10 mg/mL and 5 mg/mL, respectively. In this
aqueous phase was also introduced a fluorescent agent using
Fluorescein isothiocyanate (FITC) labeled-BSA (Sigma-Aldrich,
USA) at a 1:20 ratio (m/m) relative to BSA protein. BSA–FA
conjugate solution, previously prepared, was added at a 1:100
ratio (m/m) to the aqueous phase. The aqueous solution was
emulsified with an organic solvent (vegetable oil) by subjecting
the initial formulation to high pressure homogenization. The
drug, CORM-2, was dissolved in vegetable oil phase.
Conjugation of FA with BSA
FA (Sigma-Aldrich, USA) dissolved in PBS, pH 7.4, was
‘activated’ with 5-fold excess of N-(3-dimethylaminopropyl)-
N´-ethylcarbodiimide hydrochloride (Sigma-Aldrich, USA) and
a 1-fold excess of N-hydroxysulfosuccinimide (Sigma-Aldrich,
USA) for 2 h at room temperature. Activated FA was then added
to BSA using a 75:1 FA to BSA moles ratio, and then left to react
for 8-10 h. Dialysis against PBS was performed for 8 days in
order to remove the excess FA and other reactants from the
conjugated protein. The purified BSA–FA conjugate contained
35 mol of FA per 1 mol of BSA.Physicochemical characterization
The size distribution and zeta-potential values of the
nanoemulsions were determined at pH 7.4 (PBS buffer) and at
25 °C, using dynamic light scattering in a Malvern zetasizer NS,
by photon correlation spectroscopy (PCS) and by electrophoretic
laser Doppler anemometry, respectively. The values for viscosity
and refractive index were taken as 0.890 cP and 1.330,
respectively. The protein concentration was kept constant at
10 mg/mL.Cells and culture conditions
B-cell lymphoma cell line (A20 cell line) (ATCC, TIB-208)
was obtained from American Type Culture Collection (LGC
Standards, UK).
The A20 cell line was grown in suspension in Petri dishes,
which were not tissue culture treated (Sarstedt, Germany), using
RPMI-1640 medium supplemented with 10% (v/v) of FBS; 1%
(v/v) of penicillin/streptomycin solution; 2 mg/mL of sodium
bicarbonate; and 0.05 mM of 2-mercaptoethanol. Exponentially
growing culture was maintained in a humidified atmosphere of
5% CO2 in air at 37 °C.Protein extraction and Western blot analysis for FR
confirmation in the A20 cell line
48 h-incubated cells (KB, A20 and K562 cell lines) were
harvested, centrifuged at 2000 rpm (4 °C) for 10 min and
washed in cold PBS. Following another centrifugation, at
6000 rpm (4 °C) for 3 min, cell pellets were resuspended,
homogenized in 100 μl of ice-cooled radioimmunoprecipitation
(RIPA) buffer (1% NP-40 in 150 mM NaCl, 50 mM Tris-HCl
pH 7.5, 2 mM EDTA), supplemented with 20 mM NaF, 1 mM
phenylmethylsulfonyl fuoride (PMSF), 20 mM Na2V3O4, a
protease inhibitor cocktail (Roche, Germany), and then incubat-
ed for 10 min. The proteins were cleared by centrifugation at
10,000 ×g (4 °C) for 10 min. The soluble protein concentration
was determined using Bio-Rad DC protein assay (Bio-Rad
Laboratories, USA). The BSA was considered as a control.
40 μg of the resulting cytosolic protein extracts was separated
through 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis, and transferred onto a Hybond®-P polyvinyli-
dene difluoride membrane (GE Healthcare Life Sciences, USA).
5% (w/v) nonfat dry milk in PBS with 0.05% Tween-20 (TPBS)
was used for blocking nonspecific protein binding. After 2 h of
blocking incubation, the membrane was washed three times with
TPBS. The membrane was then incubated overnight (4 °C) with
primary antibody monoclonal rabbit to FA binding protein
(Abcam®, United Kingdom), diluted in 1% BSA (w/v) in TBST
(1:1000). Horseradish-peroxidase-conjugated secondary anti-
body (anti-rabbit IgG-HRP, Cell Signaling Technology Inc.,
USA) was diluted in 5% (w/v) nonfat dry milk in TBST
(1:30,000). Subsequent membrane incubation (1 h, room
temperature) was followed by three TPBS washes. Immobilon
solutions (Millipore, USA) were used for chemiluminescent
detection in the Chemi Doc XRS system. β-Actin was used as
loading control.
Table 1
Conditions used for nanoemulsion preparation.
BSA solution/vegetable oil ratio (v/v) 99.5%/0.5%
BSA–FITC/BSA ratio (m/m) 1/20
BSA–FA conjugate/BSA ratio (m/m) 1/100
BSA/FA (mol/mol) in BSA–FA conjugate 1/35
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A20 cell viability was studied using the Promega CellTiter
96® AQueous Non-Radioactive Cell Proliferation (MTS) assay
(Promega, USA). Cells were seeded in 24-well tissue culture
plates (Nunc, Denmark) at a density of 5 × 104 cells/well and
co-incubated with treatment conditions for determined incuba-
tion times. After co-incubation, MTS was added and the cells
were incubated for a further 4 h at 37 °C. After this period, the
absorbance of the formazan product was read at 490 nm, using
Spectra MAX 340PC microwell plate reader. Cell viability was
expressed as a percentage relative to the negative control.
Uptake assay
Unbound BSA–FITC and BSA–FA were removed using
Centricon tubes (Amicon Ultra-15, Millipore) and then the
uptake of the nanoemulsions was evaluated. A20 cells were
seeded at a density of 1 × 105 cells/well on coverslips
pre-treated with Poly-L-lysine (Sigma-Aldrich, USA), and
co-incubated with nanoemulsions for 4 h. Solutions of nanoe-
mulsions were prepared in FA-free Hanks’ Balanced Salt
solution (HBSS medium) (Lonza, Belgium). Cells were washed
with cold PBS and fixed with 500 μL of paraformaldehyde 4%
(v/v) for 30 min and then permeabilized with Triton 0.1% (v/v)
solution. After more two washing steps with PBS, cells were
incubated with 5 U/mL of Alexa Fluor 568 Phalloidin
(Molecular Probes by Life Technologies, USA). 2 μL of
Permafluor (Thermo Scientific, United Kingdom) containing
5 μg/mL of Hoechst (Molecular Probes by Life Technologies,
USA) was used for place coverslips on slides. Confocal
observations were performed using an inverted Zeiss confocal
laser scanning microscope (CLSM; Olympus Fluoview FV1000)
and three dimensional models were produced, using the software
Imaris image analysis program.
In vivo studies
All animal experiments were performed after institutional
ethical approval and in agreement with national (Portuguese
Veterinary Office) and international rules (FELASA; Federation
of Laboratory Animal Science Associations) on animal welfare.
Experiments were performed in agreement with Instituto de
Medicina Molecular Ethical Regulations and the ethical approval
was given under the project "Therapeutic evaluation of
anti-cancer drugs in mouse models of cancer” licensed to
Dr. Gonçalo Bernardes. Under those strict indications (3R’s:
reduce, replacement and refinement) the minimal number of
animals calculated was 5 mice per group, which was considered
sufficient for the purpose of this investigation. Immunocompe-
tent 10-week-old female BALB/c mice were subcutaneously
injected with A20 cells. BALB/c mice bearing subcutaneous
A20 lymphoma tumors were treated intravenously with 200 μL
of FA-functionalized nanoemulsions loaded CORM-2 (targeting
FR), 200 μL of FA-functionalized nanoemulsions (carrying no
drug), 200 μL of CORM-2 (non-targeted delivery of drug), or
saline. The dose was chosen according to the safety profile
already reported for CORM-2 in in vivo studies.11 Therapy was
initiated when tumors reached 80-120 mm3 and a daily treatmentwas performed for 5 days. The mice were sacrificed once tumor
reached a volume greater than 1000 mm3, which is the general
procedure for therapeutic assessment. The readout of the
experiment is tumor volume which can be then translated into
survival — survival here means the number of days mice took
for tumors to reach a volume greater than 1000 mm3. Mice body
weight variations, during and after therapy, and survival curves
for the different treatments applied were also determined.
Normal rodent feed contains a high concentration of FA
(6 mg/kg feed), so mice were fed an FA-free diet (Harlan diet
TD90261, Harlan Teklad) beginning 2 weeks before tumor
implantation and maintained throughout the study in order to
maintain serum FA concentrations closer to the range of normal
human serum.22,23 Being these mice most commonly used for
evaluating the performance of most anticancer agents and the
high FA levels in mice sera could negatively affect the
performance of FA-drug formulations used for cancer therapy,
the majority of “FA-targeted” pharmacological studies published
had involved the use of animals that were acclimated to some
form of low/free FA chow.23,24
Statistical analysis
Assumptions were met prior to data analysis. All data were
tested for normality (Kolmogorov–Smirnov test) and homosce-
dasticity (Levene’s test). To investigate the influence of
PEGylated BSA nanoparticles with(out) CORM-2 on cell
viability, a one-way ANOVA was conducted, with six levels:
nanoemulsions, FA-nanoemulsions, nanoemulsions + CORM-2,
FA-nanoemulsions + CORM-2, CORM-2 and death control
(30% DMSO). Post hoc comparisons were conducted using
Student–Newman–Keuls (SNK). A P value of 0.05 was used for
significance testing. Analyses were performed in STATISTICA
(StatSoft v.7, US).Results
FA-tagged protein nanoemulsions and specific uptake by FR
positive cells
We produced BSA nanoemulsions by high pressure homoge-
nization of a BSA solution, containing a PEGylated surfactant,
with vegetable oil (Table 1). The characterization of these protein
nanoemulsions is presented in Table 2 and is in line with what was
previously described by our group, demonstrating that the particles
are small, neutral surface (zeta-potential close to zero) and present
high stability along time.21 All these results establish that these
PEGylated protein nanoemulsions have suitable characteristics
required for systemic administration. Nanoemulsions containing
imaging and targeting agents were prepared by introducing of
BSA–FITC and BSA–FA conjugate in aqueous phase of initial
Table 2
Characterization of nanoemulsions and FA-tagged nanoemulsions loaded with CORM-2.
Z-average (d.nm) Polydispersity index (PDI) Zeta-potential (mV) FA concentration (μg/L)
Nanoemulsions 93.7 (±8.2) 0.157 (±0.033) −1.82 (±0.15) –
FA-Nanoemulsions + CORM-2 90.9 (±5.1) 0.152 (±0.032) −2.28 (±0.25) 449.3 (±19.7)
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particle’s surface promotes specific cell targeting and the
endocytosis, the cellular uptake of nanoemulsions was evaluated
in a B-cell lymphoma cell line (A20 cell line).
B-cell lymphoma is one of the most common hematologic
malignancies and targeted therapy based on monoclonal
antibodies has become a treatment of choice in the clinic.
However, a substantial number of patients experience a clinical
relapse as a consequence of poor or no response to the
treatments.25 Several new targeting ligands have recently
emerged for B-cell lymphoma treatment.26 We confirmed by
western blot that FR-alpha is expressed in A20 cells (Figure 1, A),
reported here for the first time. The KB cell line was used as FR
positive control and K562 cell line as FR negative control.
The evaluation of specific cellular uptake of nanoemulsions
was performed by confocal laser scanning microscopy. It was
observed that FA-functionalized nanoemulsions are more
efficiently internalized by A20 cells (Figure 1, B). These results
suggest that FA-functionalized nanoemulsions interact efficiently
with FR-alpha at the cellular surface and promote FR-mediated
endocytosis. By staining with phalloidin, which is a high-affinity
F-actin probe, we showed that the nanoparticles were indeed
internalized by the A20 cells. 3D reconstructions of images
obtained by confocal microscopy allowed determining the
number of nanoparticles internalized per cell (Figure 1, B). We
observed that, in average, approximately 7 fold more nanopar-
ticles were internalized when FA is on the particle’s surface.FA-tagged protein nanoemulsions loaded with CORM-2 and
specific drug delivery
We also evaluated the capacity of these BSA nanoemulsions
for the selective delivery of drugs into FR expressing cells. We
used CORM-2 as a model compound due to its described
anti-proliferative capacity against cancer cells and its instability
in plasma, which makes it an ideal candidate for encapsulation
and targeted delivery. Taking into account the production method
described, the prepared nanoemulsions are especially efficient for
the entrapment of hydrophobic drugs, such as CORM-2. The
physicochemical characterization of the nanoemulsions contain-
ing FA at the surface and CORM-2 encapsulated was performed
and we observed that the values of size, polydispersity index
(PDI) and zeta-potential are very similar to the values presented
by the nanoemulsions (Table 2). The quantification of FA in these
nanoemulsions was also performed using RIDASCREEN®FAST
Folic acid test kit and the results showed a high concentration of
FA at the surface of nanoemulsions (Table 2).
In order to understand the mechanism responsible for the
CORM-2 induced anti-proliferative effect observed in A20
lymphoma cells (Figure 2, A), and taking into account the
known link between CO and HO-1, we evaluated HO-1expression and ROS levels in A20 exposed to different
concentrations of CORM-2. We verified an increase of HO-1
protein expression in the presence of CORM-2, as reported in
other pathologies (e.g. in kidney cells),27 determined by Western
blot analysis (Supporting information, Figure S1), however ROS
production was not significantly altered (Supporting
information, Figure S2).
FA-functionalized nanoemulsions loaded with CORM-2 were
shown to have the same anti-proliferative effect than CORM-2
alone, which diffused across the cell membrane. This result
demonstrated that these nanoemulsions recognized the FR present
in surface of A20 cells, being internalized by FR-mediated
endocytosis and releasing the drug, as intended. Additionally, the
drug encapsulated in the nanoemulsions present several advan-
tages for in vivo applications, as previously described. This
decrease in cell proliferation is significantly different from the
anti-proliferative effect observed for the empty nanoemulsions,
whether FA-functionalized or not, and the non-targeted nanoemul-
sions containing CORM-2 (F(5,12) = 138,304, P b 0.05)
(Figure 2, B). Nanoemulsions containing CORM-2, but not FA
at the surface (non-targeted nanoemulsions), are not efficiently
internalized by A20 cells and the drug remains protected, which
explains the absence of anti-proliferative effect. These results
suggest a preferential internalization of the FA-functionalized
nanoemulsions by these FR positive cancer cells and also indicate
an effective release of the drug from nanoemulsions in vitro.
The bioavailability and targeting specificity of these
FA-functionalized PEGylated BSA nanoemulsions were also
tested in vivo. Their therapeutic efficacy was tested in BALB/c
mice bearing subcutaneous A20 lymphoma tumors. This
syngeneic model mimics human disease in an immunocompetent
host with aspects of diffuse large B-cell lymphomas,28,29 which
in our view is clinically relevant. The subcutaneous model has
additional advantages, such as providing visual confirmation that
mice do have tumors prior to therapy and easy assessment of
tumor response or growth over time.30
Figure 3, A shows a considerable tumor growth inhibition
when mice were treated with FA-functionalized nanoemulsions
loaded with CORM-2, whilst empty FA-functionalized nanoe-
mulsions were shown to have no effect. The treatment with
FA-functionalized nanoemulsions containing CORM-2 substan-
tially increased mice survival (Figure 3, B). The in vivo study
also demonstrated that the disclosed PEGylated BSA nanoemul-
sions were well tolerated in immunocompetent mice, with no
detectable weight loss (Figure 3, C).Discussion
We have developed FA-functionalized BSA nanoemulsions
that demonstrated specific drug delivery into FR positive cancer
Figure 2. In vitro therapeutic efficacy of CORM-2 and FA-tagged protein nanoemulsions loaded with CORM-2 in A20 cell line. 30% (v/v) of DMSO was
nominated as death control. To correct for variation, raw data were converted in percentage of cell viability, relative to the “cell-only” control. (A) A20 cell line
viability after 48 h of contact with different concentrations of CORM-2. Values are the mean ± SEM of 2 independent experiments. (B) A20 cell line viability
after 48 h of contact with 300 μg/mL of BSA nanoemulsions, with and without 6 μM of CORM-2 and the free-drug. Values are the mean ± SEM of 2
independent experiments. Different letters indicate significant differences among treatments (P b 0.05, one-way ANOVA).
Figure 1. Evaluation of FA-tagged protein nanoemulsions using FR positive cancer cell line. (A) β-Actin and FR-alpha protein expression in KB, A20 and
K562 cell lines analyzed by Western blot. (B) 3D representations of images obtained by confocal microscopy of nanoemulsions’ internalization in A20 cell line,
after 4 h of incubation (scale bars = 5 μm) (Blue = nuclear staining; Green = nanoemulsion particles; Red = phalloidin cytoskeleton staining).
1081A. Loureiro et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 1077–1083cells. The expression of FR-alpha was confirmed in A20
B-cell lymphoma cells that were successfully targeted by
FA-functionalized BSA nanoemulsions.
CORMs, as CO, induce specific biological responses,
through activation of a few intracellular pathways and
targets, regulating inflammation, apoptosis and cellular
proliferation.16 CO has the ability to block cancer cell
proliferation.11 It appears that CO exerts its effect through
different pathways in different cell lines and under different
conditions.11,16 One of the central targets of CO seems to be
the mithocondria and the overall bioenergetics of the cell. CO
may promote mitochondrial biogenesis and drive mitochon-
dria to increase ATP and ROS generation that in turn
influences cellular behavior. Increasing ROS production
would ultimately lead to induction of HO-1, which undercertain circumstances may generate a positive feedback loop
that contributes to the long-lasting beneficial effects of the
HO1–CO pathway, perhaps involving other HO-1 products.11
Our results indicate that in A20 cells, CORM-2 does in fact
limit cell proliferation, possibly by involving HO-1 signaling
but not affecting endogenous ROS levels.
The FA-tagged protein nanoemulsions loaded with CORM-2
led to considerable antitumor activity and the enhanced survival
of mice bearing A20 lymphoma tumors. One possibility to
explain this notable antitumor activity of FA-tagged nanoemul-
sions loaded with CORM-2 is the reported CO’s anti-cancer
effect as a result of inducing anti-Warburg effect.14 TheWarburg
effect provides substrates for cell growth and division and free
energy (adenosine triphosphate, ATP) from enhanced glucose
uptake and elevated glycolysis with a limited oxygen
Figure 3. In vivo therapeutic efficacy of FA-tagged protein nanoemulsions loaded with CORM-2. (A) Tumor growth curves of immunocompetent 10-week-old
female BALB/c mice bearing subcutaneous A20 lymphoma tumors treated intravenously with FA-functionalized nanoemulsions loaded CORM-2 (targeting
FR), FA-functionalized nanoemulsions (carrying no drug), CORM-2 (non-targeted delivery of drug), or saline. Treatment was performed daily for a period of
5 days (arrows). Data represent mean tumor volumes (±SE). Tumor growth curves were stopped when tumors reached a size of 1000 mm3. (B) Survival curves
of mice treated with FA-functionalized nanoemulsions loaded CORM-2 and control groups. (C) Mice body weight variations during and after therapy.
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compelling the cancer cell to consume more oxygen that in
turn drives metabolic demand, leading to growth inhibition,
cellular exhaustion and death.14
In the present study we chose a syngeneic model of B-cell
lymphoma in the BALB/c mouse, which mimics human disease
in an immunocompetent host. The subcutaneous model presents
advantages such as visual confirmation that mice used in an
experiment have tumors prior to therapy; and assessment to
tumor response or growth over time.30 Subcutaneous models
may however be promiscuous of small particle penetration.32
Thus the effectiveness of targeting and effect over disease
progression should be further supported, in future experiments in
vivo, in an orthotopic fat-pad model or a disseminated lymphoma
model to avoid this issue.
Small size, high stability over time, specific targeting capacity
and non-immunogenicity support their application as drug
delivery systems. Therefore, these novel FA-functionalized
PEGylated BSA nanoemulsions are promising nanocarriers for
the selective delivery of drugs to a target cell population that
express FR. In this way, these functionalized nanocarriers may
ameliorate the side effects and low efficacy of conventional
cancer treatments. Furthermore, a number of new targeting
ligands specific to B-cell lymphoma have been recently
disclosed,26 constituting attractive targets for building function-
alized protein nanoemulsions for cancer drug delivery with
maximum specificity.Acknowledgments
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